Avience Biomedicals IPO vs N R Vandana Tex Industries IPO

Comparison between Avience Biomedicals IPO and N R Vandana Tex Industries IPO.

IPO Details

Avience Biomedicals IPO is a SME Bookbuilding IPO proposed to list at NSE SME while N R Vandana Tex Industries IPO is a SME Bookbuilding proposed to list at NSE SME.

Issue Size and Price

The total issue size of Avience Biomedicals IPO is up to ₹0.00 Cr whereas the issue size of the N R Vandana Tex Industries IPO is up to ₹26.49 Cr. The final issue price of Avience Biomedicals IPO is and of N R Vandana Tex Industries IPO is ₹45.00 per share.

 Avience Biomedicals IPON R Vandana Tex Industries IPO
Face Value₹10 per share₹10 per share
Issue Price (Lower)₹42.00 per share
Issue Price (Upper)₹45.00 per share
Issue Price (Final)₹45.00 per share
Discount (Retail)₹0.00 per share
Discount (Employee)
Market Lot Size3000 shares
Fresh Issue Size15,27,600 shares58,86,000 shares
Fresh Issue Size (Amount)up to ₹0.00 Crup to ₹26.49 Cr
OFS Issue Size0 shares0 shares
OFS Issue Size (Amount)up to ₹0.00 Crup to ₹0.00 Cr
Issue Size Total15,27,600 shares58,86,000 shares
Issue Size Total (Amount)up to ₹0.00 Crup to ₹26.49 Cr

IPO Timetable

Avience Biomedicals IPO opens on , while N R Vandana Tex Industries IPO opens on May 28, 2025. The closing date of Avience Biomedicals IPO and N R Vandana Tex Industries IPO is , and May 30, 2025, respectively.

Financials & KPIs

Avience Biomedicals IPO P/E ratio is , as compared to N R Vandana Tex Industries IPO P/E ratio of 8.95.

 Avience Biomedicals IPON R Vandana Tex Industries IPO
Financials

Company Financials (Restated Consolidated)

Avience Biomedicals Ltd.'s revenue increased by 89% and profit after tax (PAT) rose by 239% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended31 Mar 202531 Mar 2024
Assets56.5234.65
Total Income45.9724.37
Profit After Tax7.292.15
EBITDA11.414.08
NET Worth22.856.23
Reserves and Surplus18.822.94
Total Borrowing22,15,820.0015.13
Amount in ₹ Crore

Company Financials (Restated)

N R Vandana Tex Industries Ltd.'s revenue increased by 23% and profit after tax (PAT) rose by 100% between the financial year ending with March 31, 2025 and March 31, 2024.

Period Ended31 Mar 202531 Mar 202431 Mar 2023
Assets202.94183.55167.96
Total Income271.10220.21195.60
Profit After Tax8.604.291.80
EBITDA19.2813.869.77
NET Worth33.7525.1617.27
Reserves and Surplus19.9325.1717.64
Total Borrowing69.0268.9865.08
Amount in ₹ Crore
Promoter Shareholding (Pre-Issue)92.85100
Promoter Shareholding (Post-Issue)66.3773.39
P/E Ratio8.95
Market Cap₹104.83 Cr.
ROE50.1417.54
ROCE24.8413.82
Debt/Equity0.972.43
EPS₹5.03
RoNW50.1415.10

Shares Offered

In the Avience Biomedicals IPO Retail Individual Investors (RII) are offered 0 shares while in N R Vandana Tex Industries IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Avience Biomedicals IPO and 11,76,000 shares in N R Vandana Tex Industries IPO.

 Avience Biomedicals IPON R Vandana Tex Industries IPO
Anchor Investor Reservation17,61,000 shares
Market Maker Reservation80,400 shares3,12,000 shares
QIB0 shares11,76,000 shares
NII0 shares8,85,000 shares
RII0 shares20,64,000 shares
Employee0 shares
Others
Total0 shares58,86,000 shares

Bids Received (Subscription)

Avience Biomedicals IPO subscribed in total, whereas N R Vandana Tex Industries IPO subscribed 101.00x.

Compare with others

Compare:

Avience Biomedicals IPO Vs N R Vandana Tex Industries IPO